NOXXON Pharma AG announces management changes
CEO Dr Frank Morich will leave the company
Iain Buchanan, who worked with the Board of Directors since 2007 and later became a Director of NOXXON Pharma AG, will assume the role of Interim CEO with effect from September 1, 2010, and will support the board during its search for a permanent replacement.
Iain has a track record and brings to NOXXON over 30 years of experience in the pharmaceutical and biotech industry. He comes to NOXXON from Novexel in Paris where, earlier this year, he was responsible for the sale of the company to Astra Zeneca. Prior to his role as CEO of Novexel Iain has held a range of management and business development positions within a number of companies in the pharmaceutical industry including Vertex, Johnson and Johnson, Biogen, and Merck & Co.
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.